Sun Pharma to invest ₹500 crore in Assam to set up manufacturing unit; shares up 1%

The stock was in the green amid news that the pharma major would invest ₹500 crore to set up a manufacturing plant in Assam. The plant will generate direct employment for over 500 people, Assam’s Chief Secretary Dr Ravi Kota said.

Senior officials of the pharma company held a meeting with the chief secretary on Wednesday and discussed various aspects of implementing the project.

"Held a meeting with representatives of Sun Pharmaceutical Industries Limited... to review the company's proposal for setting up pharmaceutical manufacturing facilities in Assam," Kota said in a post on X on Wednesday night.

From the company, senior vice president Rahul Awasthi and associate vice president Ranjit Mohapatra met Kota.

"The proposal involves establishing drug formulation manufacturing units in the state to cater to the Indian market, with a planned investment of over ₹500 crore to be implemented in two phases," the chief secretary said.

The project is expected to generate direct employment for more than 500 people in a phased manner after commencement of operations, Dr Kota added.

"Key aspects such as land requirements, availability of water and power, connectivity, and access to skilled manpower were discussed," Dr Kota said.

The company also outlined its focus on sustainable manufacturing practices, including efficient water use, increased adoption of renewable energy, and responsible waste management, in line with environmental and regulatory standards, he added.

"The meeting was part of the Assam government's ongoing engagement with prospective investors to promote employment generation, inclusive development, and long-term economic growth in the state," Kota added.

Sun Pharmaceutical is the world's fourth-largest and India's largest pharmaceutical company, with over 40 manufacturing facilities across five continents and operations in more than 100 countries, he added.

Sun Pharma Q3 FY26 Results

Sun Pharmaceutical Industries posted a 16% increase in its consolidated net profit to ₹3,369 crore for the third quarter ended December 31, 2025 (Q3 FY26), led by growth across business segments.

The Mumbai-based drug major reported a net profit of ₹2,903 crore for the October-December quarter of the last fiscal.

Total revenue from operations rose to ₹15,520 crore for the third quarter as against ₹136,75 crore in the year-ago period.

The company said its board has approved an interim dividend of ₹11 per equity share of ₹1 for the financial year 2025-26.